2023 annual financial data
Gyre Therapeutics 2023 Operating cash flow growth
Direct answer
Operating cash flow growth was 142.5%.
Operating income was -67,230,000 USD and net income was -92,933,000 USD.
Operating cash flow was 25,892,000 USD.
Get free Gyre Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 113,450,000 USD
- Operating income
- -67,230,000 USD
- Net income
- -92,933,000 USD
- Operating cash flow
- 25,892,000 USD